Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured f...
FDA Drug Recall #D-0384-2026 - Class II, March 3, 2026
Recall Summary
| Recall Number | D-0384-2026 |
| Classification | Class II - Moderate risk |
| Date Initiated | March 3, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Rising Pharma Holding, Inc. |
| Location | East Brunswick, NJ |
| Product Type | Drugs |
| Quantity | 1200 bottles |
Product Description
Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401, Country of origin: Taiwan, NDC 16571-816-51.
Reason for Recall
Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
Distribution Pattern
Nationwide within the U.S
Lot / Code Information
Lot #: 1TM0524003A, Exp. Date 09/2026.
Other Recalls from Rising Pharma Holding, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0724-2026 | Class II | Rising, Cyproheptadine Hydrochloride Syrup, 2mg... | Jul 13, 2026 |
| D-0029-2026 | Class II | Carbidopa, Levodopa, Entacapone Tablets, 25 mg/... | Oct 7, 2025 |
| D-0277-2025 | Class II | Duloxetine Delayed-Release Capsules, USP, 30 mg... | Mar 5, 2025 |
| D-0189-2025 | Class II | Duloxetine Delayed-Release Capsules USP 20 mg, ... | Dec 30, 2024 |
| D-0190-2025 | Class II | Duloxetine DR Capsules USP 60 mg, a) 30 count ... | Dec 30, 2024 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens, they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.